What question did this study set out to answer?

The study aims to evaluate the effectiveness of trastuzumab combined with chemotherapy for HER2-positive biliary tract cancers.

June 4, 2026JCO oncology advances.Open Access

Impact of Trastuzumab on Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancers: A Real-World Analysis From a High-Incidence Region (REAL TAB)

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis finds trastuzumab improves survival outcomes in HER2-positive biliary tract cancers, suggesting its routine use in treatment.

The study aims to evaluate the effectiveness of trastuzumab combined with chemotherapy for HER2-positive biliary tract cancers.
Conducted a retrospective analysis of 91 patients with HER2-positive biliary tract cancers.
Summarized patient characteristics and treatment details using descriptive statistics.
Estimated progression-free survival and overall survival using the Kaplan-Meier method.
Median progression-free survival was 11.8 months with trastuzumab versus 2.8 months without (P < .001).
Median overall survival was 17.3 months with trastuzumab versus 5.8 months without (P < .001).
The 2-year overall survival rate was 32.7% for the trastuzumab group compared to 11.8% for the control group.

Gupta et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis finds trastuzumab improves survival outcomes in HER2-positive biliary tract cancers, suggesting its routine use in treatment.